The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile

The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published Sep 23, 2016
31 pages — Published Sep 23, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

The National Institute of Allergy and Infectious Diseases (NIAID) a subsidiary of National Institutes of Health is a research institute that provides technological and therapeutic solutions. The institute develops therapies, diagnostic tests, vaccines, and other technologies to understand, immunologic, treat and prevent infectious, and allergic diseases. Its services include grants and funding, research and training, and health information. NIAID offers products for the treatment of bioterrorism, whooping cough, hepatitis A and B, rabies, meningitis, chickenpox, pneumococcal pneumonia, HIV/AIDS, malaria, tuberculosis and asthma.

The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals & Healthcare eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

  
Source:
Document ID
GDPH142862D
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 201642
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals &Healthcare Deals By Type, 2010 to YTD 201661
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals &Healthcare, Deals By Region, 2010 to YTD 201671
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals &Healthcare, Deals By Therapy Area, 2010 to YTD 201681
The National Institute of Allergy and Infectious Diseases, Medical Devices Deals, 2010 to YTD 201691
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals &Healthcare, Deals Summary, 2010 to YTD 2016102
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals &Healthcare, Deal Details1216
  Partnerships121
    Evolva Enters into Agreement with National Institute of Allergy and Infectious Diseases121
    RedHill Biopharma Enters into Agreement with NIAID131
    GlaxoSmithKline Enters into Research Agreement with NIAID141
    PepTcell Enters into Research and Development Agreement National Institute of Allergy and Infectious Diseases151
    SRI International Enters into Agreement with National Institute of Allergy and Infectious Diseases161
    Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases171
    GenVec Enters into Research Agreement with LMIV181
    GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases191
    BioAegis Therapeutics Enters into Research Agreement with the National Institute of Allergy and Infectious Disease201
    Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate212
    DFH Pharma Enters Into Co-Development Agreement With NIAID For HIV Maturation Inhibitor Drugs231
    ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases241
  Licensing Agreements251
    Butantan Institute Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases251
    Exxell BIO Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases261
    Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI271
The National Institute of Allergy and Infectious Diseases - Key Competitors281
Key Employees291
Locations And Subsidiaries301
  Head Office301
Appendix311
  Methodology311
  About GlobalData311
  Contact Us311
  Disclaimer311

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Sep 23, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/The-National-Institute-of-Allergy-and-Infectious-Diseases-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-6729>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sep 23, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/The-National-Institute-of-Allergy-and-Infectious-Diseases-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-6729>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research